1. Home
  2. SCLX vs COEP Comparison

SCLX vs COEP Comparison

Compare SCLX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$11.37

Market Cap

90.0M

Sector

Health Care

ML Signal

HOLD

Logo Coeptis Therapeutics Holdings Inc.

COEP

Coeptis Therapeutics Holdings Inc.

HOLD

Current Price

$13.51

Market Cap

100.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
COEP
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.0M
100.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCLX
COEP
Price
$11.37
$13.51
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
75.9K
68.3K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,360,000.00
$500,996.00
Revenue This Year
N/A
N/A
Revenue Next Year
$749.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$6.26
52 Week High
$34.27
$21.41

Technical Indicators

Market Signals
Indicator
SCLX
COEP
Relative Strength Index (RSI) 31.18 35.02
Support Level $11.10 $13.74
Resistance Level $13.83 $14.77
Average True Range (ATR) 0.99 0.84
MACD -0.02 -0.12
Stochastic Oscillator 8.28 0.66

Price Performance

Historical Comparison
SCLX
COEP

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: